PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
-16.18%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
7.12%
Other expenses growth 0-10% reflects moderate increase. Benjamin Graham would investigate nature of expenses.
-22.68%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-22.68%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
7.12%
D&A growth 5-10% suggests significant asset additions. Howard Marks would investigate investment returns.
22.73%
EBITDA growth above 15% demonstrates exceptional operating performance. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Operating income growth above 15% demonstrates exceptional core profitability. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
26.92%
Other expenses growth 15-30% suggests significant increase. Howard Marks would demand explanation.
22.99%
Pre-tax income growth above 15% demonstrates exceptional profitability improvement. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth above 20% signals concerning expansion. Seth Klarman would scrutinize tax strategy.
22.99%
Net income growth above 15% demonstrates exceptional bottom-line expansion. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
38.32%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
38.32%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
24.80%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
24.80%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.